Prescient Therapeutics Ltd has released a press release.
PTX OmniCAR cell manufacturing contract for clinical trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- June 2022 Quarterly Update and Appendix 4C
- US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
- Key OmniCAR Patent Granted in US
- PTX CellPryme-M presentation
- PTX unveils new clinic-ready CAR-T enhancement platform
Later from Prescient Therapeutics
- PTX agreement with Thermo Fisher for scalable OmniCAR
- Appendix 4E and 2022 Annual Report
- Prescient Therapeutics Launches Share Purchase Plan
- PTX strategic collaboration with MD Anderson Cancer Center
- PTX unveils CellPryme-A to boost CAR-T performance
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics